Disc Medicine, Inc. (NASDAQ:IRON) Shares Acquired by Woodline Partners LP

Woodline Partners LP boosted its holdings in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 5.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 396,600 shares of the company's stock after purchasing an additional 19,538 shares during the quarter. Woodline Partners LP owned about 1.33% of Disc Medicine worth $25,144,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in IRON. Tower Research Capital LLC TRC boosted its stake in Disc Medicine by 47.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock worth $52,000 after purchasing an additional 266 shares during the period. Teacher Retirement System of Texas boosted its stake in Disc Medicine by 8.9% during the 4th quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company's stock worth $308,000 after purchasing an additional 396 shares during the period. Sterling Capital Management LLC boosted its stake in Disc Medicine by 798.4% during the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock worth $36,000 after purchasing an additional 503 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in Disc Medicine by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company's stock worth $400,000 after purchasing an additional 593 shares during the period. Finally, MetLife Investment Management LLC boosted its stake in Disc Medicine by 6.6% during the 4th quarter. MetLife Investment Management LLC now owns 12,132 shares of the company's stock worth $769,000 after purchasing an additional 755 shares during the period. Institutional investors and hedge funds own 83.70% of the company's stock.

Insider Activity

In other news, Director Mona Ashiya sold 202,146 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $54.29, for a total transaction of $10,974,506.34. Following the sale, the director now owns 208,742 shares in the company, valued at $11,332,603.18. This trade represents a 49.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider William Jacob Savage sold 2,100 shares of the firm's stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $50.17, for a total value of $105,357.00. Following the sale, the insider now owns 66,398 shares in the company, valued at $3,331,187.66. This trade represents a 3.07% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 349,510 shares of company stock worth $18,936,535 over the last ninety days. 4.24% of the stock is currently owned by insiders.

Disc Medicine Stock Performance

IRON stock traded down $0.67 during midday trading on Friday, hitting $47.37. 132,011 shares of the stock were exchanged, compared to its average volume of 347,391. The stock's 50-day moving average price is $45.75 and its 200-day moving average price is $54.70. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of -11.90 and a beta of 0.77. Disc Medicine, Inc. has a fifty-two week low of $30.82 and a fifty-two week high of $68.73.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.03). Research analysts anticipate that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on IRON. Morgan Stanley reissued an "overweight" rating and issued a $85.00 target price on shares of Disc Medicine in a report on Friday, March 7th. Scotiabank boosted their target price on Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a report on Monday, March 3rd. BMO Capital Markets boosted their target price on Disc Medicine from $112.00 to $120.00 and gave the company an "outperform" rating in a report on Monday, May 12th. TD Cowen began coverage on Disc Medicine in a report on Thursday, February 27th. They issued a "buy" rating on the stock. Finally, Cantor Fitzgerald boosted their target price on Disc Medicine from $99.00 to $132.00 and gave the company an "overweight" rating in a report on Tuesday, March 18th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $98.80.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.